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Acute type A aortic dissection is a serious and 
potentially fatal condition that requires urgent 
surgical intervention. The surgical procedure can 
be complicated by major bleeding, which can 
significantly affect the outcomes. Massive blood 
transfusion could lead to many complications [1]. 
Bleeding can be either surgical, from the multiple 
suture lines and the extensive tissue dissection, or 
medical due to a coagulation defect. Therefore, it 
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Abstract 
Background: Bleeding is a serious complication after surgical repair of acute type A 
aortic dissection. Recombinant factor VIIa (rFVIIa) could be used for the 
management of severe bleeding; however, it could lead to thromboembolic events. 
We aimed to report our experience in using rFVIIa in the management of severe 
bleeding following the surgical repair of acute type A aortic dissection.  
Methods:  We performed a retrospective study, including patients who had surgery 
for acute aortic dissection type A and received rFVIIa, in the period between January 
2012 and January 2019. We reported the amount of bleeding 4 hours before and 
after the administration of rFVIIa, the number of blood products transfused before 
and after the use of rFVIIa, thrombosis of the central venous line, as well as the 
presence of disseminated intravascular coagulation. 
Results: There were ten patients (2 females and 8 males) out of 120 patients with 
acute type A aortic dissection, who required the use of rFVIIa for severe 
postoperative bleeding. The mean age was 67.7±10.5 years. The amount of drainage 
decreased from 889±585.6 ml during the 4 hours prior to the infusion, to 165±73.5 
ml during the following 4 hours (p<0.001). The patients received 2752±1362.9 ml, 
and 618±483.3 ml packed RBCs before and after rFVIIa administration, respectively 
(p< 0.001). The patients received 1601±693.4 and 246±419.6 ml of fresh frozen 
plasma before and after the use of rFVIIa, respectively (p< 0.001). The prothrombin 
time decreased after the infusion of rFVIIa (42.7±32 and 17.1±8 seconds, p= 0.001). 
There were no clinical signs of thromboembolism after its use. Mortality occurred in 
five patients (50%). 
Conclusion: In the life-threatening situation of uncontrollable bleeding following 
surgical repair of type A acute aortic dissection, rFVIIa may have benefits to control 
bleeding. Furthers studies are recommended. 
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is crucial to evaluate the efficacy of several 
medications to control bleeding, such as activated 
recombinant factor VII (rFVIIa).  
The need for extracorporeal circulation, as 
well as hypothermia during surgical repair can 
affect the coagulation process [2]. Additionally, 
many patients admitted urgently to surgery are on 
antiplatelet medications for associated ischemic 
heart disease, which can also aggravate 
postoperative bleeding [3]. 
Massive postoperative bleeding requires the 
transfusion of blood products; however, these 
measures may not be able to control life-
threatening bleeding, and the rFVIIa might have a 
role [4]. rFVIIa was initially used to treat 
hemophilia in patients with factors VIII and IX 
deficiency [5]. Moreover, rFVIIa is used for the 
management of uncontrollable bleeding in various 
clinical conditions, such as trauma, and following 
cardiac surgery [6]. 
However, rFVIIa can lead to fatal 
thromboembolic complications [7]. Thus, the 
benefits and the potential complications of its use 
must be carefully weighed and considered 
according to the severity of postoperative 
bleeding. In this study, we reported our 
experience in using rFVIIa to control severe 
bleeding following the repair of acute type A aortic 
dissection. 
Patients and Methods: 
We performed a retrospective study, including 
patients who had surgery for acute aortic 
dissection type A, and received rFVIIa 
postoperatively, in the period between January 
2012 and January 2019. Acute aortic dissection 
was defined as any dissection involving the 
ascending aorta within two weeks from the 
beginning of the symptoms. The diagnosis was 
confirmed by 3D CT angiography as well as 
intraoperatively.  
Data collection: 
The demographic data, the procedures, and 
the perioperative results were obtained from the 
surgical database. We reported the amount of 
drainage 4 hours before and 4 hours after the 
infusion of rFVIIa, the number of blood products 
transfused before and after the use of rFVIIa, 
thrombosis of the central venous line, as well as 
the presence of disseminated intravascular 
coagulation (DIC). The incidence of Myocardial 
infarction was assessed by the presence of 
persistent elevation of the ST segment in 
electrocardiography, or an increase in the cardiac 
enzymes. Cerebrovascular Stroke (CVS) was 
diagnosed by the appearance of neurologic 
deficits clinically and confirmed by computed 
tomography.  
Techniques: 
All patients were assessed with CT 
angiography, which was used for the evaluation of 
the presence of coronary lesions. Transthoracic 
echocardiography was done to evaluate the 
cardiac function, the presence and severity of 
aortic valve regurgitation, and the presence of 
pericardial collection. 
All patients were operated via median 
sternotomy. Cannulation of the femoral artery 
was performed, and we used a single right atrial 
cannula for the venous drainage. Myocardial 
protection was achieved by selective antegrade 
coronary infusion of cold blood cardioplegia 
following the aortotomy, with systemic cooling 
and topical cooling with ice slush. Venting of the 
left ventricle was done via the right superior 
pulmonary vein. The cardiologic solution was 
infused at 30 minutes intervals. 
Administration of rFVIIa was done following a 
unified protocol for patients who had severe 
uncontrollable bleeding, without a definite 
surgical cause, and after initial treatment with 
packed red blood cells (RBCs), fresh frozen plasma 
(FFP) and platelet concentrates. The infusion of 
rFVIIa was always done after the full dose of 
protamine and normalization of the activated 
clotting time (ACT) following cardiopulmonary 
bypass. The dose of rFVIIa was 60 mg/kg, repeated 
once in case of failure of the initial dose to control 
bleeding. Prothrombin time and platelet count 
were checked before and after the use of rFVIIa. 
Ethical considerations: 





No informed consent was required because of 
the severity and urgency of the condition. The 
local Ethical Committee, however, approved the 
use of rFVIIa according to the patients' prognosis. 
Statistical analysis: 
SPSS (version 20; IBM, Chicago, IL) was used to 
perform all analyses. Continuous values were 
expressed as mean ± standard deviation and 
qualitative values as number and percentage. 
Normality was tested using the Shapiro-Wilk test, 
and a paired t-test or Wilcoxon signed-rank test 
was used to compare continuous variables before 
and after rFVIIa administration. 
Results 
One hundred and twenty patients had surgery 
for acute type A aortic dissection, rFVIIa was used 
in ten patients (8.3%). There were two females 
and eight males, with a mean age of 67.7±10.5 
years. Eight patients had replacement of the 
ascending aorta, and two patients required 
additional hemi-arch replacement, with none of 
them requiring any intervention on the aortic root 
or valve. 
The mean cardiopulmonary bypass time (CBP) 
was 262.7±87.9 min, and the mean cross-clamp 
time was 151.4±52.3 min. A hypothermic 
circulatory arrest was needed in 7 patients, 
selective antegrade cerebral perfusion was used 
for 3 of them, and retrograde perfusion for four 
patients. The mean total circulatory arrest time 
was 32±27 min. 
Six patients had acute renal failure 
postoperatively, 4 of them required dialysis. Five 
patients had a severe chest infection, and one 
patient had a cerebral hemorrhage. 
The mean intensive care unit (ICU) stay was 
13.1±8 days, and the mean hospital stay was 
25.3±39 days. Mortality occurred in 5 patients 
(50%), all due to multiorgan failure (MOSF). 
The effect of rFVIIa: 
rFVIIa was given to seven patients 
intraoperatively and three patients in ICU. All 
causes of surgical bleeding were excluded. The 
bleeding profile, the blood pH, and the body 
temperature were within acceptable ranges 
before starting rFVIIa infusion. 
The severity of bleeding decreased 
significantly after the rFVIIa administration, as well 
as the number of transfused blood products. The 
amount of drainage decreased from 889±585.6 ml 
during the 4 hours prior to the infusion, to 
165±73.5 ml during the following 4 hours. (Table 
1) Two patients had surgical re-exploration, 6, and
7 hours postoperatively for hemodynamic 
instability, with suspected tamponade. No serious 
bleeding was found in both patients. 
There was a significant decrease in the 
prothrombin time (PT) following rFVIIa infusion 
(Table 1). There were no clinical signs of DIC. 
Thrombotic and hemorrhagic complications: 
One patient developed massive cerebral 
hemorrhage postoperatively, and no apparent 
reason was found. This patient went into a deep 
coma on the third postoperative day and died 12 
days postoperatively. No patient developed 
myocardial, cerebral, or mesenteric infarctions. 
There was no need to change arterial or venous 
lines due to thrombosis. No peripheral ischemic 
changes were noted in any of our patients.
Table 1: Blood products transfused and coagulation factors before and after rFVIIa infusion. Data are presented as 
mean and standard deviation. 
Before rFVIIa After rFVIIa P-Value 
Packed RBCs (ml) 2752 ± 1362.9 618 ± 483.3 <0.001 
FFP (ml) 1601 ± 693.4 246 ± 419.6 <0.001 
Platelets(ml) 731.4 ± 459 111 ± 179.7 0.002 
Prothrombin time (sec) 42.7 ± 32 17.1 ± 8 0.001 






This study was conducted on ten patients who 
developed severe uncontrollable bleeding 
following surgical management of acute type A 
aortic dissection from a total of 120 operated 
patients. This is a surgical emergency associated 
with high mortality and morbidity; one of them is 
bleeding. Hemorrhage can be caused by 
preoperative antiplatelet therapy [8], and 32% of 
the patients operated for acute aortic dissection 
had platelet dysfunction at the time of surgery 
(14% with acetylsalicylic acid alone, and 18% via a 
combination of ASA and clopidogrel). Antiplatelet 
therapy is related to the fact that the initial 
presentation of most of the patients is chest pain 
with ST-segment depression, which mimics 
ischemic heart disease. These patients are 
normally at a higher risk of intra and postoperative 
hemorrhagic complications than patients with 
normal platelet count and function [9]. 
The blood flow through the false lumen is a 
strong activator of coagulation and fibrinolysis 
prior to surgery. The extracorporeal circulation 
with associated hypothermia also could lead to 
some inhibition of the coagulation cascade, 
decreasing the synthesis of the coagulation 
factors and affecting the platelet function [10]. 
The blood contact with the tubing system 
activates the anti and procoagulants, as well as 
the complement system [11]. All these factors 
can eventually lead to severe intra and 
postoperative bleeding, requiring massive blood 
transfusion with its serious complications. 
In this case, achieving hemostasis via 
transfusion of blood products such as packed 
RBCs, FFP, and platelet concentrates can control 
bleeding in most cases. However, in our study, in 
8.3% of the patients, these measures were not 
sufficient, and persistent, life-threatening 
bleeding continued despite the absence of any 
correctable source of surgical bleeding. In such 
cases, the use of rFVIIa might be of benefit. Gill 
and colleagues concluded that the use of rFVIIa 
could be of benefit in controlling intractable 
bleeding following cardiac surgery in a 
randomized trial versus placebo. They noted, 
however, an increase in the incidence of 
thromboembolic events [5].  
The efficacy, as well as the complications of 
the usage of rFVIIa after surgical repair of acute 
aortic dissection, are not adequately evaluated. 
Tritapepe and coworkers found that rFVIIa was 
used with satisfactory results during and following 
the surgical treatment of acute aortic dissection 
using deep hypothermic circulatory arrest, to 
control massive bleeding refractory to 
conventional hemostatic measures, with 
insignificant differences in the undesirable effects 
[12]. Other case reports have reported successful 
results of its usage in the situation of refractory 
hemorrhagic shock following the surgical repair 
of acute aortic dissection [13].  
It is crucial, however, to obtain the maximum 
benefit from rFVIIa, to optimize the hemostasis, by 
maintaining a satisfactory platelet count (>50g/l), 
and by correcting anemia, hypothermia, and 
hypocalcemia [14]. Management of acidosis 
(pH<7.1), which seriously reduces the rFVIIa 
activity, is also very important [6]. 
The use of procoagulant medications can 
induce thromboembolic complications, as 
reported by many studies [15, 16]. In our study, 
no thromboembolic events were reported. There 
was a single incidence of a cerebral hemorrhage, 
not related to the rFVIIa. There were no signs of 
DIC. The low rate of complications in our study 
might be attributed to the limited number of re-
explorations after the usage of rFVIIa to detect 
thrombosis. Thus, we cannot exclude micro-
embolism as a cause for acute renal failure or 
multiorgan system failure (MOSF), which occurred 
to some of the patients enrolled in the study. 
The use of rFVIIa can, however, lead to 
activation of factor X to factor Xa through a 
systemic reaction. This leads to the production of 
a sufficient amount of thrombin, transforming 
fibrinogen into fibrin, leading to thrombus 
formation [17]. This systemic response can lead 
to thromboembolic events. Levi and colleagues, 
in their analysis of 35 controlled trials, noticed an 
increase in the incidence of arterial 
thromboembolic events with the use of rFVIIa 
compared to a placebo [18]. 





The mortality rate in patients with acute aortic 
dissection in our center was 27%, this operative 
mortality increased significantly in patients who 
developed major postoperative bleeding (50%), 
but this is not only related to the use of rFVIIa. 
Massive blood transfusion is known to be related 
to an increase in the incidence of infections, acute 
respiratory distress syndrome, multiorgan failure, 
as well as an increase in postoperative mortality 
[19]. 
rFVIIa alone cannot, however, control severe 
bleeding due to a surgical source. It is also crucial 
to adjust all other factors that may interfere with 
coagulation, such as hypothermia and acidosis, as 
well as to optimize hemostasis by transfusion of 
blood products such as FFP and platelet 
concentrates. The timing of rFVIIa infusion is very 
important, as waiting until the patient's condition 
worsens to start treatment would be of no benefit. 
Karkouti and colleagues noted that the early use 
of rFVIIa during the course of bleeding had a 
better outcome [20]. 
Limitations 
Our study has several limitations. The small 
sample size, being a single-center study, as well as 
the bias related to the retrospective study, 
concerning the patients' recruitment. Due to the 
rarity of these cases, a randomized study to 
evaluate the advantages and benefits of the use of 
rFVIIa to control severe bleeding in patients 
operated for acute aortic dissection would be very 
difficult.   
Conclusion 
This study suggests that in the critical, life-
threatening situation of uncontrollable bleeding 
following surgical repair of type A acute aortic 
dissection, rFVIIa may have benefits to control 
bleeding with low clinically evident 
thromboembolic complications. Further studies to 
confirm our findings are recommended. 
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